Merck, Inc.
🇵🇭Philippines
MK0524B Bioequivalence Study (0524B-070)
Phase 1
Completed
- Conditions
- Dyslipidemia
- Interventions
- Drug: MK0524B (ER niacin (+) laropiprant (+) simvastatin)Drug: MK0524A (ER niacin + laropiprant)Drug: Simvastatin
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2015-06-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 220
- Registration Number
- NCT00943124
A Single-Dose Study of MK6349 in Patients With Type 2 Diabetes (6349-002)
Phase 1
Terminated
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- Drug: MK6349
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2015-08-27
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 28
- Registration Number
- NCT00943371
A Study of Vaniprevir (MK-7009) in Participants With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028)
Phase 2
Completed
- Conditions
- Hepatitis C, Chronic
- Interventions
- Drug: Vaniprevir 600 mg b.i.d.Drug: Vaniprevir 300 mg b.i.d.Drug: Pegylated interferonDrug: Ribavirin
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2021-02-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00943761
A Study of V503 (A Multivalent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] Vaccine) in Preadolescents and Adolescents (V503-002)
Phase 3
Completed
- Conditions
- Cervical CancersVulvar CancerVaginal CancerGenital LesionsPAP Test AbnormalitiesHPV Infections
- Interventions
- Biological: V503
- First Posted Date
- 2009-07-22
- Last Posted Date
- 2022-10-03
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3074
- Registration Number
- NCT00943722
Phase 2 Dose-Ranging Efficacy and Safety Trial of SCH 900271 in Participants With Primary Hypercholesterolemia or Mixed Hyperlipidemia (P05675)
Phase 2
Completed
- Conditions
- Mixed HyperlipidemiaPrimary Hypercholesterolemia
- Interventions
- Drug: SCH 900271Drug: SCH 900271 15mgDrug: Placebo
- First Posted Date
- 2009-07-17
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 619
- Registration Number
- NCT00941603
Lipid Biomarker Study in Men With Dyslipidemia After Simvastatin Treatment (Study MK-0000-140)(COMPLETED)
Phase 1
Completed
- Conditions
- Hypercholesterolemia, Dyslipidemia
- Interventions
- Drug: SimvastatinDrug: Placebo
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2015-10-08
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 31
- Registration Number
- NCT00935259
Study of the Effect of Single Doses of MK2637 and Dextromethorphan on Cerebral Cortex Excitability (2637-008)
Phase 1
Completed
- Conditions
- Schizophrenia
- Interventions
- Drug: MK2637
- First Posted Date
- 2009-07-08
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 15
- Registration Number
- NCT00934466
Study of Sotatercept for the Treatment of Chemotherapy Induced Anemia in Patients With Metastatic Breast Cancer (MK-7962-012)
Phase 2
Terminated
- Conditions
- Chemotherapy Induced Anemia
- Interventions
- Biological: SotaterceptDrug: Placebo
- First Posted Date
- 2009-07-02
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00931606
- Locations
- 🇷🇺
Investigative Site, Stavropol, Russian Federation
Sitagliptin/Metformin Fed Bioequivalence Study (0431A-080)
Phase 1
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 61
- Registration Number
- NCT00929201
Fenofibrate Bioequivalence Study (0767-031)
Phase 1
Completed
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2009-06-26
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 14
- Registration Number
- NCT00928694
© Copyright 2025. All Rights Reserved by MedPath